Square Pharmaceuticals, Bangladesh’s largest drugmaker, reported a 26% year-on-year rise in net profit for the October-December quarter of the 2024-25 fiscal year, driven by higher investment income and increased earnings from associated companies.

According to its financial report, the company posted a profit of Tk 660 crore in the second quarter, up from Tk 524 crore a year earlier. Revenue also grew 13% year-on-year to Tk 1,997 crore during the period.

Investment income surged 51%, adding Tk 159 crore, while profit from associate undertakings—including Square Textile, Square Hospitals, and Square Fashions—climbed 65% to Tk 109 crore. Square Pharmaceuticals also has stakes in subsidiaries such as Square Pharmaceuticals Kenya EPZ, Square Lifesciences, and Samson Pharma.

Earnings per share rose to Tk 7.45, compared to Tk 5.92 in the same quarter last year.

Despite the strong performance, Square Pharmaceuticals’ stock fell by 0.37% to Tk 216 on Thursday.